Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NAAA | Q02083 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169636 | 1.00 | MEN1 (0.63) | MEN1CYP1A2KMT2AALDH1A1GAA | |
| SCHEMBL7511180 | 1.00 | MEN1 (0.63) | MEN1CYP1A2KMT2AALDH1A1GAA | |
| SCHEMBL7513937 | 0.92 | MEN1 (0.55) | MEN1CYP1A2KMT2AALDH1A1GAA | |
| SCHEMBL7513925 | 0.92 | MEN1 (0.55) | MEN1CYP1A2KMT2AALDH1A1GAA | |
| SCHEMBL13054366 | 0.86 | ALDH1A1 (0.57) | ALDH1A1GAATSHRNAAA | |
| SCHEMBL12404689 | 0.86 | ALDH1A1 (0.57) | ALDH1A1GAATSHRNAAA | |
| SCHEMBL753991 | 0.86 | ALDH1A1 (0.57) | ALDH1A1GAATSHRNAAA | |
| SCHEMBL19595055 | 0.84 | ALDH1A1 (0.52) | MEN1CYP1A2KMT2AALDH1A1GAA | |
| SCHEMBL7513191 | 0.84 | CTSL (0.67) | — | |
| SCHEMBL6794132 | 0.82 | ALDH1A1 (0.52) | ALDH1A1GAATSHRNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | ELI LILLY AND COMPANY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260092075-A1 | KRAS INHIBITORS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
| US-20210015816-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10646486-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180110776-A1 | POLYCYCLICCARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2018-04-26 | — | — | US | disclosed |
| US-20180110776-A1 | POLYCYCLICCARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9795602-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170119764-A1 | POLYCYCLICCARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9522912-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | GILEAD SCIENCES, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160176870-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | PHARMACIA CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1305293-A1 | HEXAHYDRO-7-IMINO-1H-AZEPIN-2-YL-HEXANOIC ACID DERIVATIVES AS INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE | Pharmacia Corporation (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2003026668-A1 | OPHTHALMOLOGIC TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026638-A1 | NEUROPROTECTIVE TREATMENT METHODS USING SELECTIVE INOS INHIBITORS | PHARMACIA CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-6495544-B2 | NITRIC OXIDE SYNTHASE INHIBITORS; ANTIIFLAMMATORY AGENTS | PHARMACIA CORPORATION | 2002-12-17 | — | — | US | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020119964-A1 | Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase | PHARMACIA CORPORATION | 2002-08-29 | — | — | US | disclosed |
| WO-2002010139-A1 | HEXAHYDRO-7-1H-AZEPIN-2-YL-HAXANOIC ACID DERIVATIVES AS INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600733-B2 | KRAS inhibitors | KRAS, NRAS, HRAS | MEN1 404/4885CYP1A2 3542/4885KMT2A 997/4885 |
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | MEN1 2174/4885CYP1A2 313/4885KMT2A 3360/4885 |
| US-20020119964-A1 | Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase | NOS2, HPD, NOS1 | MEN1 4413/4885CYP1A2 98/4885KMT2A 3980/4885 |
| US-20160176870-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | CPS1, PAICS, C9 | MEN1 2303/4885CYP1A2 367/4885KMT2A 1570/4885 |
| US-20180110776-A1 | POLYCYCLICCARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | PAICS, RPL5, CYP3A43 | MEN1 3748/4885CYP1A2 156/4885KMT2A 2897/4885 |
| US-20210015816-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | CPS1, PAICS, C9 | MEN1 2303/4885CYP1A2 367/4885KMT2A 1570/4885 |
| US-20260092075-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 511/4885CYP1A2 3258/4885KMT2A 1467/4885 |
| US-20170119764-A1 | POLYCYCLICCARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | PAICS, RPL5, CYP3A43 | MEN1 3748/4885CYP1A2 156/4885KMT2A 2897/4885 |
| US-20030109522-A1 | Ophthalmologic treatment methods using selective iNOS inhibitors | NOS2, NOS1, NOS3 | MEN1 3707/4885CYP1A2 1043/4885KMT2A 4651/4885 |
| US-10646486-B2 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | CPS1, PAICS, C9 | MEN1 2303/4885CYP1A2 367/4885KMT2A 1570/4885 |
| US-20030119826-A1 | Neuroprotective treatment methods using selective iNOS inhibitors | NOS2, NOS1, NLN | MEN1 4578/4885CYP1A2 2897/4885KMT2A 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.